Advanced Oncotherapy Preparing for commercialisation

Hardman & Co Report Report Downloads

Advanced Oncotherapy (LON:AVO) goal is to deliver an affordable and novel proton beam therapy system (PBT), based on state-of-the-art technology developed originally at the world-renowned CERN. 2018 was characterised by the achievement of a number of technical milestones, the successful integration of all the module types that constitute the LIGHT accelerator, and the acceleration of the proton beam to an energy of 52MeV, sufficient to treat superficial tumours. Meanwhile, AVO has started to gear up its commercial infrastructure through the recruitment of a Chief Commercial Officer (CCO) with experience in PBT solutions.

Strategy: AVO is developing a compact and modular PT system at an affordable price for the payor, financially attractive to the operator, and generating superior patient outcomes. AVO benefits from the technology know-how developed by ADAM, Geneva, and relies on a base of world-class suppliers.

Senior management appointment: In preparation for the commercialisation of LIGHT, AVO has appointed Moataz Karmalawy as CCO, and President for its US operations. Previously, he was General Manager worldwide for Particle Therapy Treatment at Varian Medical, a global leader and ranked #2 in PBT.

Rationale: Given his experience at Varian, and Philips Medical, Moataz will provide AVO with a wealth of knowledge in the commercialisation of PBT solutions. This appointment is a major coup for Advanced Oncotherapy and provides a considerable vote of confidence in LIGHT’s attractive proposition.

Risks: In 2018, the more complex technical challenges were overcome and progress towards a fully functional accelerator is underway in preparation for CE marking. Execution risk remains; however, establishment of an innovative financing package for providing LIGHT to potential customers has lowered this risk.

Investment summary: Demand for PBT is increasing worldwide, and the need for a small, flexible, affordable and close-to-patient system is desirable. With LIGHT, AVO is aiming to provide customers with a fully integrated PBT solution. AVO’s market capitalisation of £78m equates only to the amount of money invested into LIGHT to date, which does not reflect either the enormous technical challenges that have been overcome, or the large market potential.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Share on facebook
    Facebook
    Share on twitter
    Twitter
    Share on linkedin
    LinkedIn
    Hardman & Co

    More articles like this

    Hardman & Co

    Advanced Oncotherapy: Major milestone achieved

    Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology, developed originally at the world-renowned CERN. The complex assembly of its first LIGHT accelerator in Daresbury has been

    Hardman & Co

    Advanced Oncotherapy: LIGHT – regulatory update

    Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. The company is in the process of completing the complex assembly of

    Hardman & Co

    Advanced Oncotherapy: On the home straight

    Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. Over the past two years, important technical milestones have significantly de-risked the

    Hardman & Co

    Advanced Oncotherapy: Funded to completion

    Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. Over the past two years, important technical milestones have significantly de-risked the

    Hardman & Co

    Advanced Oncotherapy: Leveraging the modularity of LIGHT

    Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. Over the past two years, important technical milestones have significantly de-risked the

    Hardman & Co

    Advanced Oncotherapy funded through to clinical events

    AVO’s goal is to deliver an affordable and novel proton therapy (PT) system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. Over the past two years, the project has been significantly de-risked through important

    Hardman & Co

    Advanced Oncotherapy Rapidly changing to commercial execution

    Advanced Oncotherapy plc (LON:AVO) is the topic of discussion when Dr Martin Hall Analyst at Hardman & Co joins DirectorsTalk. Martin talks us through the interesting developments being made at the company, commercial deals, brings us up to date

    Hardman & Co

    Advanced Oncotherapy Confidence in LIGHT gaining momentum

    The Advanced Oncotherapy PLC (LON:AVO) goal is to deliver an affordable and novel proton beam therapy (PBT) system, based on state-of-the-art technology developed originally at the world-renowned CERN. In the past 18 months, the project has been de-risked

    Hardman & Co

    Why is Advanced Oncotherapy well positioned for the future?

    Advanced Oncotherapy plc (LON:AVO) is the topic of conversation when Dr Martin Hall, Head of Life Sciences at Hardman & Co joins DirectorsTalk. Martin talks us through some interesting developments at the company, explains what has been happening

    Hardman & Co

    Advanced Oncotherapy FLASH benefits from new US reimbursement

    Advanced Oncotherapy‘s (LON:ONC) goal is to deliver an affordable and novel proton beam therapy (PBT) system, based on state-of-the-art technology developed originally at the world-renowned CERN. In the past 18 months, the project has been de-risked through important

    Hardman & Co

    ADVANCED ONCOTHERAPY Nearing the end goal

    AVO’s goal is to deliver an affordable and novel proton beam therapy (PBT) system, based on state-of-the-art technology developed originally at the world-renowned CERN. 2018 was characterised by the achievement of a number of technical milestones, including successful

    Hardman & Co

    Advanced Oncotherapy Commercialising a breakthrough technology

    Advanced Oncotherapy (LON:AVO) goal is to deliver an affordable and novel proton beam therapy (PBT) system, based on state-of-the-art technology developed originally at the world-renowned CERN. 2018 was characterised by achievement of a number of technical milestones, the successful

    Hardman & Co

    Advanced Oncotherapy Important regulatory milestone: ISO approval

    Advanced Oncotherapy (LON:AVO)  goal is to deliver an affordable and novel proton therapy (PT) system, based on state-of-the-art technology developed originally at the CERN. Achievement of major technical milestones has boosted confidence, and the group remains on track

    No more posts to show